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Lymphangioma  is  a  localized  lymphatic  malformation,  that
occurs  more  frequently  in  the  head  and  neck.  Its  etiol-
ogy  remains  unknown;  some  authors  believe  it  consists  of
a  congenital  malformation  of  the  lymphatic  vessels,  while
others  believe  that  some  acquired  factors  lead  to  lym-
phatic  obstruction,  lymph  retention,  lymphangiectasia  and
proliferation.  Its  incidence  is  1  case  for  6000--16,000  live
births.1
It  can  occur  at  any  age,  but  approximately  50%  of  cases
are  present  at  birth  and  90%  are  diagnosed  by  2  years  of
age.  Both  genders  are  equally  affected.  The  most  common
affected  sites  are  lips,  tongue  and  neck.  Infection,  trauma
and  bleeding  can  trigger  rapid  growth  of  the  lesion.
We  report  the  case  of  a  child  diagnosed  with  submucosal
microcystic  lymphangioma  with  pharyngeal  lesions  that
required  tracheostomy  due  to  upper  airway  obstruction.
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ecannulation.
ase report
 two-month  old  male  patient  was  brought  to  the  emer-
ency  department  of  a  tertiary  hospital  in  southern  Brazil
ith  stridor  and  respiratory  effort.  He  was  submitted  to  air-
ay  endoscopy  under  general  anesthesia,  which  disclosed
haryngeal  mucosa  inﬁltration,  from  the  nasopharynx  to  the
ypopharynx,  with  upper  airway  obstruction  (Fig.  1).
The  cervical  magnetic  resonance  imaging  (MRI)  showed  a
assive  multiloculated  lesion  (4.9  ×  4.3  ×  3.6  cm3) located
n  the  retropharyngeal  space,  on  the  right  (Fig.  1  --  arrow),
xtending  posterior  and  anteriorly,  involving  the  parapha-
yngeal  space  and  the  right  parotid  deep  lobe,  as  well  as
nterior  and  laterally  displacement  of  the  contents  of  the
arotid  space,  suggestive  of  lymphatic  malformation  (lym-
hangioma).  This  diagnosis  was  conﬁrmed  by  pharyngeal
ucosa  biopsy.
The  patient  was  tracheotomized  to  ensure  airway
atency.  Sclerotherapy  with  OK-432  was  chosen  due  to  the
mpossibility  of  surgical  resection.  The  cervical  mass  was
reated  by  aspirating  5  mL,  through  cervical  ultrasound,  and
njection  of  the  same  amount  of  picibanil  at  the  site,  result-
ng  in  its  complete  regression.
 Ce´rvico-Facial. Published by Elsevier Editora Ltda. This is an open
enses/by/4.0/).
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Tigure  1  Magnetic  resonance  imaging,  showing  lesion  in  the
irway (picture  on  the  right).
Two  application  cycles  containing  2  mL  of  the  medication
ere  carried  out  in  the  airway  mucosa,  accounting  for  4
essions  each  cycle.  He  had  fever  up  to  38 ◦C  in  the  postop-
rative  period,  in  addition  to  local  pain  and  edema  following
ome  of  the  applications.
There  was  complete  regression  of  the  lesions  after  four
pplications  and,  thus,  we  chose  to  repeat  the  treatment
ycle.  After  that,  lesion  improvement  was  observed  and
he  patient  was  decannulated  at  three  years  of  age.  He
emained  asymptomatic  after  18  months  of  follow-up  fol-
owing  decannulation.
iscussion
ymphangioma  is  classiﬁed  as  macrocystic  (more  common
n  the  neck),  microcystic  (more  common  in  the  tongue
nd  cheek)  and  mixed.  Spontaneous  regression  occurs  in
.6--16%  of  cases,  with  regression  commonly  being  followed
y  recurrence.2
The  diagnosis  is  made  through  clinical  presentation  and
maging  tests,  such  as  cervical  ultrasound  and  MRI,  which
eﬁne  the  size  and  extent  of  the  disease.2
The  main  goal  of  treatment  is  to  restore  function  preser-
ation  and  esthetic  integrity.3 It  should  be  individualized
or  each  patient,  depending  on  the  size  of  the  lesion,
ts  location  and  the  presence  of  complications  --  bleed-
ng,  recurrent  infection,  obstructive  symptoms,  esthetic
eformities.4 Small  lesions  without  functional  or  esthetic
nvolvement  require  no  treatment.  Due  to  the  fact  that  it
s  an  inﬁltrative  lesion  without  clear  limits,  the  involvement
f  vital  structures  can  complicate  the  management  of  this
athology  and  result  in  its  incomplete  resection,  as  well  as
erve  and  blood  vessel  damage.4
In  some  mildly  symptomatic  cases  there  are  reports  of
esion  involution  in  15%--70%  of  cases;  such  children  can  be
ollowed  until  the  age  of  ﬁve  years.4
Surgical  resection  is  the  deﬁnitive  treatment  and  it
s  indicated  in  lesions  larger  than  3  cm,  with  progressive
l
d
aopharynx  to  the  right  (arrow).  Endoscopic  image  of  the  upper
rowth,  bone  erosion,  dyspnea,  dysphagia  or  esthetic
eformity.4 The  surgery  is  recommended  after  6  months  of
ge,  unless  the  children  develop  compressive  symptoms  that
ay  indicate  an  earlier  surgery.4 Surgical  treatment  is  also
ndicated  for  localized  microcystic  lesions.2 The  lymphan-
ioma  can  impair  the  airway  by  extrinsic  compression  or
ntrinsic  involvement.  Airway  involvement  is  more  common
n  childhood  or  after  acute  hemorrhage  in  a  macrocystic
esion,  requiring  early  treatment  or  tracheostomy.  Prenatal
etection  can  help  plan  the  need  for  treatment  outside  the
terus,  during  delivery  (Ex-Utero  Intrapartum  Treatment  --
XIT).3
The  surgical  mortality  rate  can  be  up  to  6%,  and  the  rate
f  complications  ranges  from  19%  to  33%.  The  recurrence
ate  is  up  to  53%.4
Other  current  treatments  include  radiation  therapy,
aser,  and  sclerotherapy  with  OK-432,  doxycycline,  sodium
orrhuate,  dextrose,  tetracycline,  hypertonic  saline  solu-
ion,  acetic  acid,  ethanol,  cyclophosphamide,  interferon,
brin  glue,  corticosteroids4 or  boiling  water.1
Radiotherapy  may  be  indicated  in  recurrent  and  persis-
ent  cases  that  remain  symptomatic  or  as  an  adjuvant  to
urgery.  However,  there  is  a  risk  of  malignancy  develop-
ent,  and  a  series  of  cases  showed  it  was  not  an  effective
reatment.2
Endoscopic  laser  resection,  either  with  CO2 or  YAG,
llows  a  more  accurate  lesion  removal,  without  functional
mpairment.2 However,  large  lesions  will  possibly  require
ther  associated  therapies.  It  could  be  an  alternative  treat-
ent  for  palliative  cases.4
The  95%  or  100%  alcohol  solution  is  the  most  potent  scle-
osing  agent,  but  can  damage  the  vascular  endothelium  and
enature  the  proteins  and  cause  thrombosis.  Adverse  effects
nclude  nerve  damage,  pain,  edema,  systemic  symptoms.
he  safe  amount  to  be  used  in  young  children  with  large
esions  is  limited  and  often  inefﬁcient.4
Bleomycin  is  a cytotoxic  antibiotic  that  induces  degra-
ation  of  deoxyribonucleic  acid,  causing  lesion  sclerosing
nd  ﬁbrosing.2 At  low  doses,  symptoms  can  occur  at  the
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Response  to  OK-432  sclerotherapy  in  the  treatment  of  cervic
application  site  and  a  clinical  picture  similar  to  a  common
cold.  The  risk  of  using  this  drug  is  dose-dependent  pulmonary
ﬁbrosis.1
Doxycycline  is  a  broad-spectrum  antibiotic  that  cause
ﬁbrosis  and  prevents  lesion  cell  proliferation.  Due  to  the
discomfort  of  the  injection,  it  should  be  applied  under  gen-
eral  anesthesia  and  pain-control  medication  are  needed
after  the  procedure.3 It  seems  to  be  more  effective  in  the
treatment  of  microcystic  lymphangioma.  It  can  cause  tooth
pigmentation.4
The  injection  of  corticoids,  such  as  triamcinolone,2
seems  to  be  effective  in  intraoral  cavernous  hemangiomas,
being  effective  in  selected  cases  of  cervical  lymphangioma.
Infection  may  be  an  adverse  effect.
Few  authors  have  reported  on  the  use  of  ﬁbrin  glue,
which  would  act  as  a  hemostatic  agent  and  would  elimi-
nate  the  dead  spaces  in  the  cysts;  no  side  effects  have  been
reported.4
Interferon-alpha  2a  has  shown  to  be  effective  in  a  small
group  of  children,  but  it  is  not  extensively  used  due  to  its
adverse  effects:  fever,  nausea,  diarrhea,  weight  loss,  liver
enzyme  abnormalities,  alopecia,  neutropenia,  headaches.4
The  intralesional  use  of  cyclophosphamide  was  described
in  a  study  on  life-threatening  tumors.  The  most  common
adverse  effects  are:  bone  marrow  suppression,  hemor-
rhagic  cystitis,  liver  dysfunction  and  long-term  malignant
transformation.4
OK-432  or  picibanil  is  a  biological  preparation  contain-
ing  Streptococcus  pyogenes  strains  treated  with  benzathine
penicillin.  After  its  injection  into  the  lymphangioma,  it
stimulates  the  proliferation  of  lymphatic  endothelial  cells
and  obstruction  of  lymphatic  channels.  Its  concentration  is
0.1  mg/10  mL.  The  dose  should  not  exceed  20  mL2 per  appli-
cation,  although  there  have  been  reports  on  30  mL  use.5
It  is  believed  that  endothelial  damage  caused  by  picibanil
is  secondary  to  the  activation  of  the  host  immune  sys-
tem.  The  biggest  disadvantage  of  using  it  is  the  risk  of
hemodynamic  repercussions,  especially  in  those  allergic  to
penicillin.  Fever  up  to  39 ◦C  often  occurs  within  6  h  after
injection,  which  remits  in  approximately  4  days  with  the  use
of  antipyretic  drugs,1 which  was  conﬁrmed  in  the  outcome
of  our  patient.
OK-432  leads  to  complete  response  in  macrocystic
lesions,  with  a  lower  degree  of  response  in  mixed
5 PRESS
mphangioma  3
r  microcystic  lesions.3 Polycystic  lesions  show  inferior
esults.3 Similarly,  the  suprahyoid  macrocystic  or  micro-
ystic  lesions  and  infrahyoid  microcystic  lesions  are  more
ifﬁcult  to  handle  than  infrahyoid  macrocystic  and  poste-
ior  cervical  lesions.  The  reason  for  this  discrepancy  is  yet
o  be  clariﬁed.3
If  the  lesion  does  regress  within  90  days,  a  new  applica-
ion  with  up  to  20  mL  can  be  performed.
Several  reports  have  concluded  that  OK-432  is  safe  and
ffective  for  the  treatment  of  lymphangiomas5 and  it  seems
o  reduce  the  need  for  adjuvant  therapies.3
inal considerations
here  are  few  reports  about  the  effects  of  treatment
ith  OK-432  in  microcystic  submucosal  lymphangiomas  in
atients  who  required  tracheostomy.  There  is  little  evidence
n  each  therapeutic  measure  and  most  of  them  are  based
n  case  reports  or  series  of  cases.  This  is  the  ﬁrst  report  on
he  use  of  this  medication  in  this  type  of  lesion  that  allowed
atient  decannulation.
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